Germline variation of the melanocortin-1 receptor does not explain shared risk for melanoma and thyroid cancer

Experimental Dermatology

Volumn 18, Issue 6, 2009, Pages 548-552

  Bauer, Jürgen ^a,b   Weng, Julie ^c   Kebebew, Electron ^c,d   Soares, Paula ^e   Trovisco, Vitor ^e   Bastian, Boris C ^b,d  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

BRAF; MC1R; Melanoma; Susceptibility gene; Thyroid carcinoma

Indexed keywords

B RAF KINASE; MELANOCORTIN 1 RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; PROTEIN EXPRESSION; RISK ASSESSMENT; RISK FACTOR; THYROID CANCER;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CELLS, CULTURED; COHORT STUDIES; EPITHELIAL CELLS; ETHNIC GROUPS; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HAIR COLOR; HUMANS; MALE; MELANOCYTES; MELANOMA; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PORTUGAL; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, MELANOCORTIN, TYPE 1; RISK; RNA, MESSENGER; SAN FRANCISCO; SPAIN; THYROID NEOPLASMS; YOUNG ADULT;

EID: 66149100968     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2008.00827.x     Document Type: Article

References (21)

1. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002: 417: 949-954.
2. Maldonado JL, Fridlyand J, Patel H et al. Determinants of BRAF mutations in primary melanomas. J Natl Cancer Inst 2003: 95: 1878-1890.
3. Landi MT, Bauer J, Pfeiffer RM et al. MC1R germline variants confer risk for BRAF-mutant melanoma. Science 2006: 313: 521-522.
4. Fargnoli MC, Pike K, Pfeiffer RM et al. MC1R variants increase risk of melanomas harboring BRAF mutations. J Invest Dermatol 2008: 128: 2485-2490.
5. Altshuler D, Brooks LD, Chakravarti A, Collins FS, Daly MJ, Donnelly P. A haplotype map of the human genome. Nature 2005: 437: 1299-1320.
6. Gerstenblith MR, Goldstein AM, Fargnoli MC, Peris K, Landi MT. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum Mutat 2007: 28: 495-505.
7. John PR, Makova K, Li WH, Jenkins T, Ramsay M. DNA polymorphism and selection at the melanocortin-1 receptor gene in normally pigmented southern African individuals. Ann N Y Acad Sci 2003: 994: 299-306.
8. Motokawa T, Kato T, Hongo M et al. Characteristic MC1R polymorphism in the Japanese population. J Dermatol Sci 2006: 41: 143-145.
9. Peng S, Lu XM, Luo HR, Xiang-Yu JG, Zhang YP. Melanocortin-1 receptor gene variants in four Chinese ethnic populations. Cell Res. 2001: 11: 81-84.
10. Valverde P, Healy E, Jackson I, Rees JL, Thody AJ. Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995: 11: 328-330.
11. Kennedy C, ter Huurne J, Berkhout M et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001: 117: 294-300.
12. Brudnik U, Branicki W, Wojas-Pelc A, Kanas P. The contribution of melanocortin 1 receptor gene polymorphisms and the agouti signalling protein gene 8818A>G polymorphism to cutaneous melanoma and basal cell carcinoma in a Polish population. Exp.Dermatol. 2008: Epub ahead of print, PMID:18637131.
13. HESTON WE, Vlahaki G. Influence of the Ay gene on mammary-gland tumors, hepatomas, and normal growth in mice. J Natl Cancer Inst 1961: 26: 969-983.
14. Kuklin AI, Mynatt RL, Klebig ML et al. Liver-specific expression of the agouti gene in transgenic mice promotes liver carcinogenesis in the absence of obesity and diabetes. Mol Cancer 2004: 3: 17.
15. Wolff GL, Roberts DW, Galbraith DB. Prenatal determination of obesity, tumor susceptibility, and coat color pattern in viable yellow (Avy/a) mice. The yellow mouse syndrome. J Hered 1986: 77: 151-158.
16. Klebig ML, Wilkinson JE, Geisler JG, Woychik RP. Ectopic expression of the agouti gene in transgenic mice causes obesity, features of type II diabetes, and yellow fur. Proc Natl Acad Sci U S A 1995: 92: 4728-4732.
17. Xing M. BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007: 28: 742-762.
18. Canchola AJ, Horn-Ross PL, Purdie DM. Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 2006: 163: 521-527.
19. Goggins W, Daniels GH, Tsao H. Elevation of thyroid cancer risk among cutaneous melanoma survivors. Int J Cancer 2006: 118: 185-188.
20. Su AI, Wiltshire T, Batalov S et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A 2004: 101: 6062-6067.
21. Trovisco V, Soares P, Preto A et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005: 446: 589-595.